Status:
COMPLETED
Renal Biomarkers in AKI and COVID-19
Lead Sponsor:
Instituto Nacional de Enfermedades Respiratorias
Conditions:
Coronavirus Infection
Covid19
Eligibility:
All Genders
18-70 years
Brief Summary
Severe pneumoniae related to Coronavirus Disease (COVID-19), had a high in-hospital mortality; this condition are worst in subjects with acute kidney disease (AKI); conditioning increased mortality, d...
Detailed Description
The usefulness of urinary NGAL levels and the platelet / lymphocyte index as predictive markers of AKI in the context of COVID-19 will be studied. These results will allow to propose more appropriate ...
Eligibility Criteria
Inclusion
- Subjects over 18 years of age.
- Subjects admitted with a diagnosis of probable SARS-CoV-2 pneumonia.
- Subjects with a diagnosis of SARS-CoV-2 pneumonia confirmed by Real-time quantitative-Polymerase Chain Reaction (qRT-PCR).
- Subjects with qRT-PCR negative for SARS-CoV-2, but who meet clinical and radiological criteria for COVID-19, and no other causes have been identified.
Exclusion
- Pregnant women
- Incomplete medical records.
- Elimination criteria:
- Patients who die within the first 24 hours of entering the institute.
- Patients discharged for any reason not considered death within the first 48 hours, such as voluntary discharge or transfer to other health institutions.
- Patients who during their hospitalization report a positive PCR for other non-respiratory viruses without identifying SARS-CoV-2
- Patients who withdraw their consent
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT04517630
Start Date
June 1 2020
End Date
September 30 2021
Last Update
June 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Investigacion en Enfermedades Infecciosas
Mexico City, Mexico, 14060